Medis
Medis is an Icelandic pharmaceutical out-licensing company, founded in 1985 and backed by Teva, that develops generic tablets, capsules, and injections in-house and licenses them to 400+ marketing authorization holders across 100+ countries. It generates revenue through licensing fees, royalties, and product supply agreements supported by dedicated BD/CX teams and the Medis Now online portal.
- Company typePrivate
- Founded1985
- HeadquartersHafnarfjörður, Iceland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medis does
Medis ehf is a privately held Icelandic pharmaceutical out-licensing company, founded in 1985 and headquartered in Hafnarfjörður, Iceland, that operates as a separately run business unit within Teva Pharmaceutical Industries Ltd. The company specializes in developing generic pharmaceutical products in-house, primarily tablets, capsules, and injections, with a portfolio of approximately 185-200+ products spanning oncology, cardiovascular, antiinfectives, nervous system, alimentary tract and metabolism, blood and blood forming organs, respiratory, musculo-skeletal, genito-urinary, and systemic hormonal therapeutic areas. Its core technology and asset base comprise comprehensive registration dossiers prepared in eCTD, ANDA, and Canadian formats, plus serialization services supporting compliance with the EU Falsified Medicines Directive, all backed by Teva's development and manufacturing infrastructure.
Medis monetizes through a B2B out-licensing model that combines upfront licensing fees, ongoing royalties, and product supply agreements with third-party pharmaceutical companies and marketing authorization holders globally. It supports over 400 marketing authorization holders and more than 5,500 marketing authorizations across 100+ countries, delivered through a dedicated enterprise field sales motion in which each customer is assigned a business development manager and a customer experience manager, supported by a 24/7 ERP-integrated online customer portal (Medis Now). Regional teams and offices in Canada, Italy, Spain, Brazil, Australia, and the UAE cover Europe, North America, LATAM, MENA, and Oceania, with active participation in DCAT Week and CPhI events for BD lead generation. All production facilities are GMP-approved, and Medis holds no AI/ML capabilities, with technology focused on regulatory dossier preparation, serialization, and digital customer operations.
Medis firmographics
Firmographics- Name
- Medis
- Legal name
- Medis ehf
- Website
- https://medis.is
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Medis is an Icelandic pharmaceutical out-licensing company, founded in 1985 and backed by Teva, that develops generic tablets, capsules, and injections in-house and licenses them to 400+ marketing authorization holders across 100+ countries. It generates revenue through licensing fees, royalties, and product supply agreements supported by dedicated BD/CX teams and the Medis Now online portal.
- Ownership category
- akta.pro rank
Medis industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where Medis is headquartered
LocationHeadquarters
- HQ city
- Hafnarfjörður
- HQ country
- Iceland
- HQ region
- Europe
Offices7 records
Markets served
Medis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Licensing: Medis out-licenses generic pharmaceutical products to third-party pharmaceutical companies worldwide. The company develops products in-house and provides regulatory support, manufacturing, and supply. Revenue is generated through product licensing agreements with upfront fees and ongoing royalties.
- Pharmaceutical Product Supply: Supply of generic pharmaceutical products including tablets, capsules, and injections to licensed partners. Revenue generated through product sales under supply agreements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Medis product offering
Product offeringCore offering
Medis out-licenses a portfolio of 200+ generic pharmaceutical products (tablets, capsules, injections, oral liquids) to third-party pharmaceutical companies worldwide. The company develops products in-house and provides comprehensive regulatory dossiers (ANDAs, eCTDs, Canadian dossiers), manufacturing, serialization, and supply chain services, supporting marketing authorizations in 100+ countries. Strong focus on oncology and metabolic therapeutic areas.
Product overview
Medis is a pharmaceutical out-licensing company offering a unified platform of generic pharmaceutical products and services. The core offering is a portfolio of 200+ generic pharmaceutical products (tablets, capsules, injections, oral liquids) across therapeutic areas including oncology, cardiovascular, antiinfectives, and nervous system. This is complemented by the Medis Now online customer portal for order management and reporting, supported by registration dossiers, regulatory affairs services, business development management, customer experience support, launch coordination, and supply chain management services. The company operates as part of Teva Pharmaceutical Industries Ltd., drawing on their development and manufacturing capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Pharmaceutical Products Portfolio Broad portfolio of 200+ generic pharmaceutical products in tablets, capsules, injections, oral liquids, and modified release formulations covering oncology, cardiovascular, antiinfectives, nervous system, alimentary tract and metabolism, blood and blood forming organs, respiratory systems, musculo-skeletal system, genito-urinary system, and systemic hormonal preparations. Licensed to third-party pharmaceutical companies worldwide.
- Medis Now Online Customer Portal 24/7 online customer portal enabling customers to place orders, view order histories, access reports, graphs, and live data on orders, download invoices and documents, and monitor forecast accuracy. Directly connected to Medis resource planning systems.
- Registration Dossiers
- Regulatory Affairs Services
- Serialization Services
- Business Development Services
- Customer Experience (CX) Services
- Launch Coordination Services
- Supply Chain Management
Quantifiable outcome
- Regulatory approvals secured prior to patent expiry
- +2 more outcomes
Companies that use Medis
Customer profileSegments1 record
Ideal customer profiles1 record
Medis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Medis partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights6 records
Medis competitors and assessment
Company assessmentBroad incumbents
- Sandoz (Novartis): Large global generic and biosimilar pharmaceutical division of Novartis, with finished generics across virtually all therapeutic areas plus biologics/biosimilars. Comparable as a global generic developer/supplier across all of Medis' target therapeutic and geographic segments.
- Teva Pharmaceutical Industries Ltd. Parent company of Medis and one of the world's largest generic pharmaceutical manufacturers with global manufacturing, regulatory, and distribution infrastructure across essentially every therapeutic area and major market. Included as the parent incumbent that defines Medis' manufacturing and capital backbone.
- Aurobindo Pharma Limited: Large Indian-headquartered generic and specialty pharmaceutical manufacturer with broad finished generics (oral solids, injectables) supplied globally through partner/distribution channels. Comparable in finished-generic supply model and as a cost-competitive competitor in Medis' served markets.
Direct peers
- Gedeon Richter Plc. Hungarian-based specialty and generic pharmaceutical company with international out-licensing, finished-dose generics (tablets, capsules, injectables), and substantial regulatory dossier expertise across markets. Strong functional overlap with Medis in B2B generic licensing and supply.
- Alvotech: Biosimilar-focused company that develops products in-house and out-licenses them to commercial partners for regulatory, manufacturing, and supply purposes across multiple regions. The capital-light out-licensing model is closely analogous to Medis' generic out-licensing approach.
- Apotex Inc. Canadian-headquartered generic pharmaceutical developer and manufacturer with a large finished generics portfolio and international out-licensing/sourcing operations. Directly comparable as a generic out-licensor with regulatory dossiers and supply across multiple countries.
- Stada Arzneimittel AG: Major European generic and specialty pharmaceutical company that out-licenses and supplies generic products (including specialty generics) to partner companies, with a multi-country commercial footprint. Highly comparable to Medis' B2B generic out-licensing and supply model.
- Polpharma Biuro Handlowe: Polish-based generic pharmaceutical company with vertical integration from API to finished dosage forms, supplying tablets, capsules, and injectables to international partners. Comparable finished-generic, multi-market supply model with strong European presence.
- Hikma Pharmaceuticals PLC: Specialty and generic pharmaceutical company with strong MENA heritage that develops, licenses, and supplies a broad portfolio of finished-dose generics globally. Comparable in product breadth (tablets, capsules, injectables), out-licensing/sales mix, and presence in markets Medis targets.
- KRKA, d.d., Novo Mesto: Slovenian generic pharmaceutical manufacturer with broad finished-dose generics portfolio (tablets, capsules, injectables) that licenses and supplies products internationally across 100+ markets — a near-direct comparator in product form factors, out-licensing/revenue model, and geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Medis social profiles
Digital presenceMedis compliance and trust
Trust signalCompliance2 records
Medis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medis leadership team
Management profileNumber of profiles
Profiles9 records
Medis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medis
What does Medis do?
Medis out-licenses a portfolio of 200+ generic pharmaceutical products (tablets, capsules, injections, oral liquids) to third-party pharmaceutical companies worldwide. The company develops products in-house and provides comprehensive regulatory dossiers (ANDAs, eCTDs, Canadian dossiers), manufacturing, serialization, and supply chain services, supporting marketing authorizations in 100+ countries. Strong focus on oncology and metabolic therapeutic areas.
Is Medis a public or private company?
Medis is a private company. It is classified as corporate owned and is currently operating.
When was Medis founded?
Medis was founded in 1985. It employs 51 to 100 people.
Where is Medis based?
Medis is headquartered in Hafnarfjörður, Iceland, in the Europe region.
How does Medis make money?
Two revenue lines are on record. Generic Pharmaceutical Licensing is the primary driver. The others are pharmaceutical Product Supply.
Who are Medis's main competitors?
Broad incumbents on record are Sandoz (Novartis), Teva Pharmaceutical Industries Ltd. and Aurobindo Pharma Limited. Direct peers are Gedeon Richter Plc., Alvotech, Apotex Inc., Stada Arzneimittel AG, Polpharma Biuro Handlowe, Hikma Pharmaceuticals PLC and KRKA, d.d., Novo Mesto.
Does Medis have an API?
No public API is recorded for Medis.
What industry is Medis in?
Medis's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.